The buccal cell micronucleus (MN) assay, first proposed by Stich et al. (1, 2) , is useful as a biomarker of genetic damage caused by life-style habits (e.g. consumption of tobacco products and alcohol, micronutrient deficiency), exposures to environmental pollutants (e.g. pesticides, arsenic, formaldehyde), medical procedures (e.g. radio-and/or chemotherapy), as well as, inherited genetic defects in DNA repair (1-18).
The non-invasive nature of this technique makes it an attractive candidate for the bio-monitoring of human populations or individuals. However, the increased use of the MN assay in buccal cells, has led to a wide diversity in techniques, timing for cell collection relative to exposure period, cell and nuclear staining procedures, numbers and types of cells analysed, and scoring criteria for micronuclei (MNi) and other nuclear anomalies (e.g. karyorrhexis, condensed chromatin, pycnosis, karyolysis, 'broken egg' or nuclear buds; 4,5). Additionally, a lack of knowledge regarding the biological and biochemical bases of these various nuclear anomalies often seen in buccal cells may lead to confusion in distinguishing normal homeostatic responses from pathological effects at the genome or chromosome level. This confusion is compounded by the use of various staining methods that may or may not be DNA-specific and may or may not lead to the staining of structures that resemble MNi (e.g. keratohyalin granules, clumps of bacteria), and could lead to inclusion of false positive MNi in the MN frequency value (19). Furthermore, the issue of whether MNi should be scored solely in the basal layer of buccal epithelia, or in terminally differentiated exfoliated cells, and whether the scoring should be limited to cells with an intact 'normal' nucleus and/or 'degenerated' cells (i.e. differentiated cells showing other nuclear anomalies) remains unresolved. The number of scored cells required to determine statistically meaningful changes in MN frequency also needs to be carefully examined (20, 21) . These uncertainties in procedure and interpretation may potentially hinder the wider use of this method in bio-monitoring and preclude efforts to perform meta-analysis of data collected from different laboratories.
Consequently, in an attempt to resolve the important outstanding issues outlined above, the HUMN project (www. humn.org) has decided to focus its attention on the human buccal MN assay. The strategy will be similar to that developed for the cytokinesis-block MN assay in lymphocytes (22) (23) (24) and has been planned to occur in the following stages: 
